Myelofibrosis-Associated Lymphoproliferative Disease: Retrospective Study of 16 Cases and Literature Review by Etienne, A. et al.
Hindawi Publishing Corporation
Advances in Hematology
Volume 2009, Article ID 179847, 5 pages
doi:10.1155/2009/179847
Clinical Study
Myeloﬁbrosis-Associated Lymphoproliferative Disease:
Retrospective Study of 16 Cases and Literature Review
A. Etienne,1 B. Gruson,1 D.Chatelain,2 R.Garidi,1 B. Royer,1 H.Sevestre,2
J. P. Marolleau,1 andG.Damaj1
1Department of Clinical Hematology, Centre Hospitalier Universitaire, University Hospital of Amiens,
1 Place Victor Pauchet, 80000 Amiens, France
2Department of Clinical Pathology, University Hospital of Amiens, 1 Place Victor Pauchet, 80000 Amiens, France
Correspondence should be addressed to G. Damaj, damaj.gandhi@chu-amiens.fr
Received 15 July 2009; Accepted 9 October 2009
Recommended by Maher Albitar
Background. To better describe the clinical, biological, and the outcome of non-Hodgkin’s lymphoma (NHL) with, at the initial
presentation, bone marrow ﬁbrosis (MF). Patients and Methods. From January 2001 to January 2007, 16 eligible patients with
NHL and MF were retrieved from the Pathology Department of the University hospital of Amiens. Median age of patients was
62 years (range 16–74) with a sex ratio male/female of 3. Results. MF is associated with all types of lymphoma predominantly
with B-cell phenotype and it seems to be more associated with low-grade NHL. B-symptoms are more frequent at diagnosis and
more patients presented with an elevated LDH level. JAK-2 was negative in the 10 patients analysed. Two patients presented with
featuresofprimaryMFwithnoevidence oflymphoma.Overallresponseratewas94%aftertheﬁrstlineoftherapywithregression
or improvement of MF. Relapse occurred in 8 patients (47%) with recurrence of MF in all of them. After a median follow-up of 42
months, 12 patients were alive with an overall survival rate for the entire group of 75%. Conclusions. MF-associated NHL is a rare
manifestation which may be associated with all types of NHL and its presence does not seem to confer a poor prognosis. A search
for lymphoproliferation should be considered when the cause of MF is not apparent.
Copyright © 2009 A. Etienne et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Myeloﬁbrosis (MF) is characterized by the accumulation
of reticulin and collagen ﬁbers and the proliferation of
ﬁbroblastic mesenchymal cells in the bone marrow in
association with increased neoangiogenesis and circulating
levels of particular cytokines such as TGF-β1, PDGF, and
FGF-β [1].
MF can be classiﬁed into two categories: primary idio-
pathic (IMF) and secondary process occurring at the onset
or in the course of the disease. Chronic myeloproliferative
neoplasms (polycythemia vera, essential thrombocythemia,
or chronic myeloid leukemia) represent one of the fre-
quent causes of secondary MF followed by autoimmune
myeloﬁbrosis or other nonhematologic disorders [2]. The
association between MF and lymphoproliferative disease is a
very rare event and is not well described except in multiple
myeloma [3] and hairy cell leukemia. Few cases reported
theassociationbetweenMFandlymphoproliferation[4–16].
However, the true incidence of this association, the clinical
characteristics, and the prognosis of the patients are not
known.
In this report, we review literature and describe the
clinical characteristics and outcome of 16 patients with lym-
phoproliferative disorders associated, at diagnosis, with MF.
2. Patients andMethods
2.1. Patients. From January 2001 to January 2007, 25
previously untreated patients with the diagnosis of lympho-
proliferative disease and bone marrow MF on initial bone
marrow (BM) evaluation were retrieved from the archives of
the Department of Pathology of the University Hospital of
Amiens. To be eligible for the study, patients with B- or T-
cell lymphoproliferative diseases should have MF based on
the initial bone marrow histology examination.2 Advances in Hematology
2.2. Diagnostic and Staging Procedures. Medical ﬁles and
histological blades of all patients were re-examined. Patients
with the diagnosis of hairy cell leukemia were excluded
because of its frequent and known association with BM
ﬁbrosis. The diagnostic work-up and staging procedures on
presentation included patient history and complete physical
examination, full blood cell count, serum lactate dehydro-
genase (LDH), β2-microglobulin, liver enzymes, alkaline
phosphatase and creatinine levels, albumin level, chest X-ray,
and computed tomography (CT) scan of the chest, abdomen
and the pelvis. Patients were staged according to the Ann
Arbor staging system. The mutational status for JAK2V617F
was determined retrospectively in 10 patients using a PCR
assay as described [17].
2.3. Histological Assessment of Bone Marrow Fibrosis. Bone
marrow biopsy samples were ﬁxed in formalin and brieﬂy
decalciﬁed before paraﬃn embedding. Semithin (3μm-
thick) sections were obtained and stained with hematoxylin
phloxyn saﬀron, Masson’s trichrome, and Gordon-Sweet
reaction. Myeloﬁbrosis was graded independently by two
pathologists. Grading of reticulin ﬁbrosis was according
to the quantity and pattern of distribution of reticulin
on a scale of 0 to 3, following the recommendations of
the European consensus [18]. The category of no ﬁbrosis
was termed “MF0”, with scattered linear reticulin with no
intersections (cross-overs). The category of mild ﬁbrosis was
termed “MF1” with a loose network of reticulin with many
intersections, especially in perivascular areas. The category
of moderate ﬁbrosis was termed “MF2” with a diﬀuse
and dense increase in reticulin with extensive intersections,
occasionally with only focal bundles of collagen and/or focal
osteosclerosis. The category of severe ﬁbrosis was termed
“MF3” with a diﬀuse and dense increase in reticulin with
extensive intersections with coarse bundles of collagen, often
associated with signiﬁcant osteosclerosis.
3. Results
3.1. Patient Characteristics. Of the 25 patients reported with
a diagnosis of lymphoproliferative disease and BM ﬁbrosis,
nine cases were excluded due to the diagnosis of hairy
cell leukaemia (n = 1), multiple myeloma (n = 1), and
incomplete medical records (n = 7). Thus, a total of 14
cases were ﬁnally analyzed. The diagnosis of lymphoma was
done on lymph nodes biopsy in 16 patients. The other
two patients had lymphoma conﬁned to the bone marrow.
There was a clear male predominance with 12 males (75%)
and 4 females (25%). Median age at diagnosis was 62
years (range, 16–74). In most cases, clinical characteristics
were dominated by B symptoms (n = 11, 69%) and
splenomegaly (n = 8; 50%). Eight patients presented
with low-grade lymphoma (follicular lymphoma (n = 5),
lymphocytic lymphoma/chronic lymphocytic leukemia (n =
2), lymphoplasmacytic lymphoma (n = 1)). High-grade
lymphomas were documented in 5 patients (B-DLCL, n = 3;
Burkitt lymphoma, n = 1, T-cell lymphoblastic lymphoma,
n = 1) and three patients presented with mantle cell
Table 1: Clinical and biological features of myeloﬁbrosis associated
lymphoma patients.
N( % )
Patients 16
Age (years)
Median (range) 62 (16–74)
Sex
Male/female 12/4 (75/25)
Lymphoma histology
Low grade 8 (50)
MCL 3
DLCL 3
others 2
Bs y m p t o m s
Positive 11 (69)
negative 5
Splenomegaly
yes 8 (50)
no 8 (50)
LDH level (UI/L)
normal 6 (38)
elevated 10 (62)
WBC count
median (range) (109/L) 8.4 (3.0-20.7)
Hb level
median (range) (g/dl) 12 (8.4–15)
platelets count
median (range) (109/L) 165 (50–444)
Dacryocytes
Positive/negative/na 1/12/3
Leucoerythrocytic features
Positive/negative/na 3/10/3
FLIPI
0–1 1/5 (20)
>1 4/5 (80)
Myeloﬁbrosis grading
Mild 9 (56)
Moderate 6 (37)
Severe 1
N◦ lines chemotherapy
1–3 lines 15 (93)
>3 lines 1
Overall response rate 94%
Overall survival (months) 72
DLCL: diﬀuse large cell lymphoma; FLIPI: follicular lymphoma interna-
tional prognostic index; LDH: lactate dehydrogenase; MCL: mantle cell
lymphoma; WBC: white blood cells; Hb: hemoglobin.
lymphoma. Most of the patients (n = 11; 69%) had ECOG
scale of less than 2. B-symptoms were found in 11 patients
(11/17; 69%) including follicular lymphoma (n = 2/5), B-
DLCL (n = 3/3) mantle cell lymphoma (n = 2/3). LDH level
w a se l e v a t e di n1 0p a t i e n t s( 6 2 % ) .T h eI P Is c o r ew a sm o r e
than1inallpatientswithB-DLCLandMCL.TheFLIPIscoreAdvances in Hematology 3
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wasmorethan1in4/5ptswithfollicularlymphoma.Median
white blood cell (WBC) was 8.4k/L (3.0–20.7), hemoglobin
level at 12g/dl (8.4–15), and platelets count at 165k/L (50–
444). Three patients (19%) had low white WBC count, 8
had anemia (50%), and 5 had thrombocytopenia (31%).
Myeloﬁbrosis was graded mild in 9 patients, moderate in
6 patients, and severe in one patient. No signs of atypical
megakaryocytes or myeloproliferation have been observed.
JAK2V617F mutation was negative in the 10 patients analysed.
Patients received a median of 1 treatment line (range,
1–8). One patient had autologous stem cell transplantation
(mantle cell lymphoma). Eleven patients (68%) reached
complete remission (CR), 4 patients (25%) had had partial
remission(PR),andonepatientwasprogressiveaftertheﬁrst
lineofchemotherapy.BMhistologywasevaluated,attheend
of therapy, in 8 patients (CR = 5; PR = 3). MF disappeared
in 4 patients (3 patients who were in CR and 1 in PR from
lymphoma) and improved in 4 others. Relapse occurred in 8
patients (50%); ﬁve of them were in CR at the end of the ﬁrst
line of chemotherapy with disappearance of MF in 3 patients
and mild ﬁbrosis in 2 patients; three patients were in PR with
onlyonepatientwithnoﬁbrosisaftertheﬁrstlineoftherapy.
BM analysis, at relapse, showed mild (n = 2) and moderate
(n = 3) myeloﬁbrosis in all of them.
After a median follow-up of 42 months, 12 (75%)
patients were alive, 9 in CR, 2 in PR and 1 with progressive
disease. Median overall survival (OS) and disease free
survival (DFS) were 72 months, and 61 months respectively.
4. Discussion
In addition to primary and postchronic myeloproliferative
disorders, myeloﬁbrosis may be associated with a large
subset of diseases such as autoimmune disorders or lym-
phoproliferativediseases.Lymphoidmyeloﬁbrosisrepresents
a particular and rare entity in which medullary ﬁbrosis
associated with abnormal lymphoproliferation replaces nor-
mal hematopoiesis. Hairy cell leukemia is one of the most
known lymphoma in which MF is frequently encountered;
however, the association with other lymphoproliferation is
rarely described. Rare cases have been reported in multiple
myeloma, T-cell lymphoma, marginal cell, and lymphoplas-
matoid cell lymphoma [3, 4, 12, 16]( Table 2). However, the
clinical characteristics and the prognosis of such association
are not well known.
Over a period of seven years, 375 cases were registered,
with the diagnosis of lymphoma, in the records of the
department of pathology. Twenty-ﬁve of them were asso-
ciated with bone marrow ﬁbrosis which implies a crude
incidence of 6.6%. In this study, Myeloﬁbrosis was not
speciﬁc for a type of lymphoma; however we note in this
group of patient a relatively more frequent association
of myeloﬁbrosis with low-grade non-Hodgkin lymphoma
(8/16; 50%). B-symptoms were frequently present (12/16;
75%), and the LDH level was elevated in 62% of patients at
initial presentation. It is important to note that two patients
presented with features of idiopathic myeloﬁbrosis without
any signs of peripheral lymphoproliferation. The diagnosis
of lymphoma in those two patients was done after more than
one bone marrow biopsy and immunophenotyping of bone
marrow cells. The other clinical and biological parameters
were unremarkable (Table 1). MF was mild to moderate in
all cases. One patient presented with osteomyelosclerosis and
did not respond to chemotherapy. JAK2V617F was negative
in the ten cases analyzed. JAK2V617F i sf o u n di n5 0p e r c e n t
of primary myeloﬁbrosis cases. The observation that none
of our lymphoproliferative disease-associated cases were
positive for this mutation suggests a distinct etiology from
PMF.Responsetotherapywassatisfactory(CR = 75%;PR =
25%), with a relapse rate, DFS, and OS not diﬀerent from
lymphoma without myeloﬁbrosis. However, the prognostic
value of the persistence of MF after chemotherapy cannot
be determined in this small group of patient. Cytokines
produced by megakaryocytes and monocytes such as PDGF,
TGF-β,V E G Fa n dβ-FGF have been shown to play an
important role in the development of secondary stromal
proliferation, and the TGF-β secreted by the tumor cells has
been suggested to play an important role in the development
of MF conferring a direct relation between lymphoma and
MF. In our group of patient, the concomitant regression of
MF with the response of lymphoma to chemotherapy and its
reappearance with relapse argue for a direct relation between
the tumor cell and myeloﬁbrosis.
Inconclusion,secondarymyeloﬁbrosistonon-Hodgkin’s
lymphoma is rare and seems to be more associated with
low-grade lymphoma. The clinical course and prognosis are
not diﬀerent from lymphoma without MF. A search for
lymphoproliferation should be considered when the cause of
MF is not apparent.
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